Bill Patalon is scaring us with MDR Pathogens in his latest teaser ad for his Private Briefing service, of course not without a convincing reason. MDR Pathogens by the way is a medical term for referring multiple drug resistant pathogens, to be specific contagious bacterial infections that are hostile to treatment through most of the antibiotics available to a Medical practitioner.
Let’s ponder over some quotes from his thinly obfuscated ad.
Unfortunately, a pandemic has crossed our borders.
Deadly and highly contagious superbugs known as MDR Pathogens are spreading rapidly throughout our cities and small towns.
At this very moment, infectious disease specialists from the CDC are closely monitoring for MDR Pathogen outbreaks in eight major metro areas.
A few more please…
If you have the opportunity, in the early stages, to purchase stock in a pharmaceutical company that has developed a new antibiotic, the rewards can be immense.
Take Pfizer. With a market cap of over $200 billion, it is an enormous drug company.
And yet, after they released the antibiotic Zithromax, their stock shot up 405%.
Well, that’s a trick enough to make you read his pitch and scrape around your greed for the riches the investment opportunity offered in the ad for Bill Patalon’s private briefing service.
Let’s quickly get on with the task of deciphering the ad.
Staphylococcus aureus (MRSA) is a bacteria that causes infections in different parts of the body and it’s tougher to treat the condition because it has resistance to most of the commonly used antibiotics, more often called a Superbug – and there’s another one Clostridium Difficile a kind of MDR Pathogen has been very much in the news of late – it’s particularly scary when there are reports of it spreading from health care centers, don’t worry it’s very much curable in most individuals who contract the infection.
Its quiet obvious that the ad is harping about the next range of antibiotics, antibiotics have been ignored by the big drug companies of late. Perhaps the cheap generic versions are sufficient for treatment of most of the conditions, more so because of heavy research expenditure involved in developing a new antibiotic. So also many of us are just fine with the good old Penicillin and other cheap antibiotics.
I feel it’s just because of the incentives showered at the developers by way of longer patent lives, R & D grants and fresh regulations for stocking up on strategic drugs, etc. by the regulators have led to a fresh impetus to look for the next big thing in pharma. I am of an investing philosophy to look for stocks at the underlying value of a company rather than at what the newsletter vendors say.
While the hunt for the stock being hyped in this teaser ad continues, more of my insights into the current scenario pertaining to MDR Pathogens and the nitty-gritty of ‘Miracle on Mount Ararat’ would be the essence of my next article until then stay tuned.